First Time Loading...

Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 762.7 USD -1.81% Market Closed
Updated: May 2, 2024
LLY
/
Income Statement
/
Revenue

Eli Lilly and Co
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eli Lilly and Co
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
ZTS

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Eli Lilly and Co
NYSE:LLY
Revenue
$34.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
4%
Johnson & Johnson
NYSE:JNJ
Revenue
$81.8B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$45.5B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$58.5B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Revenue
$61.4B
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
3%
Zoetis Inc
NYSE:ZTS
Revenue
$8.5B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
6%

Eli Lilly and Co
Revenue Breakdown

Breakdown by Geography
Eli Lilly and Co

Total Revenue: 34.1B USD
100%
United States: 21.8B USD
63.9%
Outside United States: 12.3B USD
36.1%
Europe: 6.2B USD
18.1%
Other Foreign Countries: 2.9B USD
8.6%
Japan: 1.7B USD
4.9%
China: 1.5B USD
4.5%
Show More
Show Less

Breakdown by Segments
Eli Lilly and Co

Total Revenue: 34.1B USD
100%
Net Product Revenue: 28.8B USD
84.4%
Collaboration And Other Revenue: 5.3B USD
15.6%
Diabetes And Obesity: 4.9B USD
14.3%
Oncology: 2.9B USD
8.4%
Jardiance: 2.7B USD
8%
Neuroscience: 2.2B USD
6.4%
Immunology: 1.7B USD
5.1%
Olumiant: 922.6m USD
2.7%
Basaglar: 728.3m USD
2.1%
Other: 662.9m USD
1.9%
Tyvyt®: 393.4m USD
1.2%
Trajenta: 386.9m USD
1.1%
Collaboration And Other Revenue Associated Wi...: 191.6m USD
0.6%
Show More
Show Less

See Also

What is Eli Lilly and Co's Revenue?
Revenue
34.1B USD

Based on the financial report for Dec 31, 2023, Eli Lilly and Co's Revenue amounts to 34.1B USD.

What is Eli Lilly and Co's Revenue growth rate?
Revenue CAGR 10Y
4%

Over the last year, the Revenue growth was 20%. The average annual Revenue growth rates for Eli Lilly and Co have been 12% over the past three years , 10% over the past five years , and 4% over the past ten years .

ALPHA SPREAD
Join more than 133,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.